STOCK TITAN

Dyadic International (DYAI) Financials

DYAI NASDAQ
Trailing 12 months to September 30, 2026
Revenue $3.1M -7.6% YoY
Net Income -$7.0M n/m YoY
EPS (Diluted) -$0.21 n/m YoY
Operating Cash Flow -$7.0M n/m YoY
Market Cap $11.5M as of Nov 20, 2026
Price / Sales 3.7x on $3.1M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DYAI SEC filings page.

Dyadic International, Inc. (DYAI) reported $3.1M in revenue over the twelve months to Sep 30, 2026, down 7.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DYAI FY2025

The numbers show a business whose operations still consume cash while financing increasingly supports a shrinking equity base.

FY2025’s gross margin fell 40.9 percentage points as revenue fell 11.6%, reversing the prior year’s unusually high margin. Operating cash flow was -$5.7M despite reported liquidity measuring 15.4 months of latest annual operating outflow, so the balance-sheet cushion was not being replenished by core activity.

Liabilities rose to 87.6% of assets in FY2025 from 28.5% in FY2023, marking a sharp shift toward creditor claims. Total equity was $1.2M against liabilities at 7.1x equity, making the balance sheet more dependent on financing than its 2.7x current ratio alone suggests.

R&D consumed 69.7% of revenue while SG&A consumed 186.4% in FY2025, leaving little room for the commercial contribution to absorb overhead. Gross profit was $770K, so the business’s commercial contribution remained too small to cover its operating cost structure.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 52 / 100
Financial Health Score 52/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Dyadic International, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
42

Dyadic International, Inc. held $7.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $5.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Dyadic International, Inc. scores 42/100 among other emerging companies.

Dilution
53

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Dyadic International, Inc. scores 53/100 on it among other emerging companies.

R&D Intensity
53

Dyadic International, Inc. spent $2.2M on research and development in fiscal year 2025, which was 21.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Dyadic International, Inc. scores 53/100 among other emerging companies.

Revenue Progress
47

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Dyadic International, Inc. scores 47/100 on it among other emerging companies.

Burn Trend
57

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Dyadic International, Inc. scores 57/100 on it among other emerging companies.

Balance Sheet
57

Dyadic International, Inc.'s cash, cash equivalents and investments came to $7.3M at the end of fiscal year 2025, against $8.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Dyadic International, Inc. scores 57/100 among other emerging companies.

Altman Z-Score Distress
-13.69

Dyadic International, Inc. scores -13.69, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $93.5M against total assets of $9.9M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
1/8

Dyadic International, Inc. passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing
N/A

Dyadic International, Inc. reported a net loss of $7.4M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$449K
YoY-61.4%
QoQ-53.3%
5Y CAGR-8.3%

Dyadic International, Inc. generated $449K in revenue in Q3 2026. This represents a decrease of 61.4% from the same quarter a year earlier. Against the prior quarter it is down 53.3%.

Net Income
-$1.4M
YoYn/m
QoQn/m
5Y CAGRn/m

Dyadic International, Inc. reported a net loss of $1.4M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.04
YoYn/m
QoQn/m

Dyadic International, Inc. earned -$0.04 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$3.9M
YoY-32.7%
QoQ+175.5%
5Y CAGR-22.1%

Dyadic International, Inc. held $3.9M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
40M
YoY+10.8%
QoQ+10.0%
5Y CAGR+7.4%

Dyadic International, Inc. had 40M shares outstanding in Q3 2026. This represents an increase of 10.8% from the same quarter a year earlier. Against the prior quarter it is up 10.0%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
16.5%
YoY+4.4pp
QoQ+18.9pp

Dyadic International, Inc.'s gross margin was 16.5% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 4.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 18.9 percentage points.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$430K
YoY-24.8%
QoQ+29.3%
5Y CAGR-25.7%

Dyadic International, Inc. invested $430K in research and development in Q3 2026. This represents a decrease of 24.8% from the same quarter a year earlier. Against the prior quarter it is up 29.3%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

DYAI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DYAI quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$449K-61.4%$961K-0.6%$1.1M+182.3%$566K-30.8%$1.2M-40.5%$967K+150.5%$394K+17.6%$817K+19.1%
Cost of Revenue$375K-63.4%$984K+60.4%$792K+166.0%$385K+9.0%$1.0M+158.7%$614K+103.2%$298K+106.8%$353K+0.8%
Gross Profit$74K-47.4%-$23K-106.5%$319K+232.7%$181K-61.1%$141K-91.0%$353K+320.6%$96K-49.7%$465K+38.1%
R&D Expenses$430K-24.8%$333K-47.2%$476K-3.8%$458K-16.0%$572K+24.3%$629K+22.1%$495K-5.3%$546K-36.0%
SG&A Expenses$1.5M-2.1%$1.7M+17.6%$1.8M+10.0%$1.2M-13.4%$1.5M+14.1%$1.4M-10.6%$1.6M-10.7%$1.4M-12.8%
Operating Income-$1.8Mn/m-$2.1Mn/m-$1.9Mn/m-$1.5Mn/m-$1.9Mn/m-$1.7Mn/m-$2.0Mn/m-$1.5Mn/m
Income TaxN/AN/A$0N/AN/AN/AN/AN/A
Net Income-$1.4Mn/m-$2.1Mn/m-$2.0Mn/m-$1.6Mn/m-$2.0Mn/m-$1.8Mn/m-$2.0Mn/m-$1.6Mn/m
EPS (Basic)-$0.04n/m-$0.06n/m-$0.05n/m-$0.06n/m-$0.06n/m-$0.06n/m-$0.07n/m-$0.05n/m
EPS (Diluted)-$0.04n/m-$0.06n/m-$0.05n/m-$0.06n/m-$0.06n/m-$0.06n/m-$0.07-$0.05
Diluted Shares (Avg)38M+12.4%36M+21.0%36M+21.8%N/A34M+15.5%30M+2.8%30MN/A

Not reported in any period shown, so not listed: EBITDA, Interest Expense.

DYAI Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DYAI quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$7.9M-32.0%$6.5M-19.7%$7.8M-1.1%$9.9M+0.2%$11.7M+8.0%$8.1M-23.4%$7.9M-37.7%$9.9M+20.8%
Current Assets$7.9M-31.8%$6.4M-13.5%$7.7M-1.3%$9.9M+0.7%$11.5M+8.0%$7.4M-29.5%$7.8M-37.8%$9.8M+21.8%
Cash & Equivalents$3.9M-32.7%$1.4M-33.4%$4.2M-16.1%$4.6M-29.0%$5.8M-1.5%$2.1M-65.1%$5.1M-52.1%$6.5M-0.1%
Short-Term Investments$647K-79.1%$1.7M-40.6%$1.4M-41.0%$2.7M-2.1%$3.1M-22.5%$2.8M-28.3%$2.3M+57.2%$2.8M+268.4%
Accounts Receivable$1.5M+66.2%$1.3M+82.1%$996K+349.4%$1.1M+360.0%$917K+159.7%$715K+186.3%$222K-9.9%$237K-49.2%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0
Total Liabilities$10.5M+16.0%$8.9M+3.0%$8.2M+17.9%$8.7M+16.8%$9.1M+22.6%$8.7M+16.2%$7.0M-14.6%$7.5M+218.7%
Current Liabilities$4.6M+14.7%$3.9M+6.0%$3.2M+62.3%$3.7M+50.6%$4.1M+95.1%$3.7M+87.9%$2.0M-13.3%$2.4M+8.7%
Non-Current Liabilities$5.9M+16.9%$5.0M+0.7%$5.0M+0.5%$5.0M+0.3%$5.0M-5.7%$5.0M-9.2%$5.0M-15.1%$5.0M+5539.7%
Total Equity-$2.6M-198.9%-$2.4Mn/m-$408K-144.1%$1.2M-50.1%$2.6M-23.6%-$530K-116.7%$924K-79.5%$2.5M-58.0%
Retained Earnings-$98.9Mn/m-$97.5Mn/m-$95.4Mn/m-$93.5Mn/m-$91.9Mn/m-$89.9Mn/m-$88.1Mn/m-$86.1Mn/m

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

DYAI Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DYAI quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$1.5Mn/m-$1.8Mn/m-$2.0Mn/m-$1.8Mn/m-$1.9Mn/m-$130Kn/m-$1.9Mn/m-$696Kn/m
Stock-Based Compensation$142K-17.7%$144K-57.6%$139K-38.1%N/A$172K-30.3%$340K+14.4%$225K-26.6%N/A
Investing Cash Flow$1.2M+1135.0%-$357Kn/m$1.3M+162.6%$468K-62.9%$93Kn/m-$962Kn/m$482Kn/m$1.3M+3598.8%
Financing Cash FlowN/AN/AN/A-$1-100.0%$4.9Mn/m$0n/m$24K-99.6%$24Kn/m

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

DYAI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DYAI quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin16.5%+4.4pp-2.4%-38.9pp28.7%+4.4pp32.0%-24.9pp12.1%-67.7pp36.5%+14.8pp24.4%-32.6pp56.8%+7.8pp
Operating Margin-403.6%-213.7%-171.3%-271.6%-165.3%-178.9%-508.8%-187.2%
Net Margin-302.2%-221.0%-176.0%-277.1%-169.7%-185.6%-515.2%-189.7%
Return on EquityN/AN/AN/A-127.2%-64.4pp-75.8%-69.8ppN/A-219.5%-175.0pp-62.8%-27.5pp
Return on Assets-17.1%-0.2pp-32.5%-10.5pp-25.0%+0.6pp-15.8%-0.1pp-16.9%-15.0pp-22.0%-2.8pp-25.7%-9.8pp-15.6%+9.6pp
Current Ratio1.69-1.2x1.65-0.4x2.42-1.6x2.68-1.3x2.85-2.3x2.02-3.4x3.98-1.6x4.01+0.4x
Liabilities-to-EquityN/AN/AN/A7.07+4.1x3.48+1.3xN/A7.55+5.7x3.02+2.6x
Asset Turnover0.060.0x0.150.0x0.14+0.1x0.060.0x0.10-0.1x0.12+0.1x0.050.0x0.080.0x

Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Dyadic International, Inc. DYAI FY2025 $3.1M -$7.4M N/A $11.5M 52/100
Lisata Therapeutics, Inc. LSTA FY2025 $170K -$16.6M N/A $9.7M —
Dare Bioscience, Inc. DARE FY2025 $1.0M -$13.4M N/A $8.0M 55/100
BioCardia, Inc. BCDA FY2025 $0 -$8.2M N/A $11.9M —
Allarity Therapeutics, Inc. ALLR FY2025 $320K -$11.2M N/A $12.6M —
Pluri Inc. PLUR FY2026 $1.0M -$23.8M N/A $13.5M 42/100

Frequently Asked Questions

Dyadic International, Inc. (DYAI) reported $3.1M in total revenue for fiscal year 2025. This represents a -11.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Dyadic International, Inc. (DYAI) revenue declined by 11.6% year-over-year, from $3.5M to $3.1M in fiscal year 2025.

No, Dyadic International, Inc. (DYAI) reported a net loss of $7.0M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $7.4M.

Dyadic International, Inc. (DYAI) reported diluted earnings per share of -$0.23 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Dyadic International, Inc. (DYAI) had a gross margin of 24.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Dyadic International, Inc. (DYAI) has a return on equity of -597.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Dyadic International, Inc. (DYAI) recorded an outflow of $5.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Dyadic International, Inc. (DYAI) had $9.9M in total assets as of fiscal year 2025, including both current and long-term assets.

Dyadic International, Inc. (DYAI) invested $2.2M in research and development during fiscal year 2025.

Dyadic International, Inc. (DYAI) had 36M shares outstanding as of fiscal year 2025.

Dyadic International, Inc. (DYAI) had a current ratio of 2.68 as of fiscal year 2025, which is generally considered healthy.

Dyadic International, Inc. (DYAI) had a liabilities-to-equity ratio of 7.07 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Dyadic International, Inc. (DYAI) had a return on assets of -74.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Dyadic International, Inc. (DYAI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $11.5M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Dyadic International, Inc. (DYAI) trades at 3.7x sales, its market capitalization divided by $3.1M revenue, trailing 12 months to September 30, 2026. The market capitalization is $11.5M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Dyadic International, Inc. (DYAI) held $7.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.7M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Dyadic International, Inc. (DYAI) has an Altman Z-Score of -13.69, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Dyadic International, Inc. (DYAI) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Dyadic International, Inc. (DYAI) reported a net loss of $7.4M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Dyadic International, Inc. (DYAI) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top